Head and Neck Cancer Clinical Trial
Official title:
Efficacy of EPA-enriched Supplement Compared With Standard Formula on Body Weight Changing in Malnourished Head and Neck Cancer Patients Undergone Surgery: A Randomized Study
NCT number | NCT02321631 |
Other study ID # | REC 57-073-13-1 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 2015 |
Est. completion date | March 2018 |
Verified date | March 2020 |
Source | Prince of Songkla University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to study the effects of EPA-enriched supplement compared with conventional supplement in malnourished head and neck cancer patients undergone surgery. Primary outcome is perioperative weight changing.
Status | Completed |
Enrollment | 70 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Patients diagnosed as Head an Neck cancer with pathological confirmation 2. Receiving surgery as a primary treatment 3. Malnutrition screening tool(MST) is 2 or more Exclusion Criteria: 1. Previously irradiated patient in the Head and Neck region 2. Previously receiving chemotherapy 3. Renal insufficiency with serum creatinine > 2.5 mg/dL 4. Liver function abnormality with total serum bilirubin > 3.0 mg/dL 5. Pregnancy |
Country | Name | City | State |
---|---|---|---|
Thailand | Prince of Songkla University | Hatyai | Songkhla |
Lead Sponsor | Collaborator |
---|---|
Prince of Songkla University |
Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in Body weight at 3 weeks | Body weight measured in kilogram | 3 weeks | |
Primary | Change from baseline in Body weight at 1 month | Body weight measured in kilogram | 1 month | |
Primary | Change from baseline in Body weight at 3 months | Body weight measured in kilogram | 3 months | |
Secondary | Change from baseline in fat-free mass percentage at 3 weeks | Percent of fat-free mass on the Bioelectrical Impedance Analysis (BIA) | 3 weeks | |
Secondary | Change from baseline in fat-free mass percentage at 1 month | Percent of fat-free mass on the Bioelectrical Impedance Analysis (BIA) | 1 month | |
Secondary | Change from baseline in fat-free mass percentage at 3 months | Percent of fat-free mass on the Bioelectrical Impedance Analysis (BIA) | 3 months | |
Secondary | Change from baseline in body fat percentage at 3 weeks | Percent of body fat on the Bioelectrical Impedance Analysis (BIA) | 3 weeks | |
Secondary | Change from baseline in body fat percentage at 1 month | Percent of body fat on the Bioelectrical Impedance Analysis (BIA) | 1 month | |
Secondary | Change from baseline in body fat percentage at 3 months | Percent of body fat on the Bioelectrical Impedance Analysis (BIA) | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |